The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Hepatic Overexpression of Endothelial Lipase Lowers High-Density Lipoprotein but Maintains Reverse Cholesterol Transport in Mice: Role of Scavenger Receptor Class B Type I/ATP-Binding Cassette Transporter A1-Dependent Pathways
Abstract
Objective—: Reverse cholesterol transport (RCT) is a major mechanism by which HDL (high-density lipoprotein) protects against atherosclerosis. Endothelial lipase (EL) reportedly reduces HDL levels, which, in theory, would increase atherosclerosis. However, it remains unclear whether EL affects RCT in vivo. Approach and Results—: Adenoviral vectors expressing EL or luciferase were intravenously injected into mice, and a macrophage RCT assay was performed. As expected, hepatic EL overexpression markedly reduced HDL levels. In parallel, plasma 3 H-cholesterol counts from the EL-expressing mice decreased by 85% compared with control. Surprisingly, there was no difference in fecal 3 H-cholesterol excretion between the groups. Kinetic studies revealed increased catabolism/hepatic uptake of 3 HDL-cholesteryl ether, resulting in no change in fecal HDL-cholesteryl ester excretion in the mice. To explore underlying mechanisms for the preservation of RCT despite low HDL levels in the EL-expressing mice, we investigated the effects of hepatic SR-BI (scavenger receptor class B type I) knockdown. RCT assay revealed that knockdown of SR-BI alone reduced fecal excretion of macrophage-derived 3 H-cholesterol. Interestingly, hepatic EL overexpression under SR-BI inhibition further attenuated fecal tracer counts as compared with control. Finally, we observed that EL overexpression enhanced in vivo RCT under pharmacological inhibition of hepatic ABCA1 (ATP-binding cassette transporter A1) by probucol. Conclusions—: Hepatic EL expression compensates for reduced macrophage-derived cholesterol efflux to plasma because of low HDL levels by promoting cholesterol excretion to bile/feces via an SR-BI pathway, maintaining overall RCT in vivo. In contrast, EL-modified HDL might negatively regulate RCT via hepatic ABCA1. Despite extreme hypoalphalipoproteinemia, RCT is maintained in EL-expressing mice via SR-BI/ABCA1-dependent pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
EL belongs to the same lipase family as LPL, but targets phospholipids on the shell of high-density lipoproteins (HDL), leading to decreased HDL levels.
“EL belongs to the same lipase family as LPL, but targets phospholipids on the shell of high-density lipoproteins (HDL), leading to decreased HDL levels (119–122).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
Huby, T., Doucet, C., Dachet, C., Ouzilleau, B., Ueda, Y., Afzal, V., Rubin, E., Chapman, M. J., & Lesnik, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26893 · Cited by 124
Flagged first, then by citations
Research works printed but not linked: 43
- 10.1080/07853890310020635 · DOI
- 10.1038/nrcardio.2009.94 · DOI
- 10.1056/NEJMoa1001689 · DOI · Paper page
- 10.1016/S0022-2275(20)30466-1 · DOI · Paper page
- 10.1172/JCI16306 · DOI
- 10.1172/JCI16146 · DOI
- 10.1172/JCI37176 · DOI
- 10.1074/jbc.M406360200 · DOI
- 10.1194/jlr.M500366-JLR200 · DOI
- 10.1161/CIRCGENETICS.111.962613 · DOI
- 10.1016/j.atherosclerosis.2010.04.004 · DOI
- 10.1172/JCI25327 · DOI · Paper page
- 10.1074/jbc.274.4.2366 · DOI
- 10.1161/CIRCULATIONAHA.110.009704 · DOI
- 10.1074/jbc.M304367200 · DOI
- 10.1038/35042675 · DOI · Paper page
- 10.5551/jat.14.133 · DOI
- 10.1161/CIRCRESAHA.107.151746 · DOI
- 10.1161/01.ATV.0000193513.29074.52 · DOI
- 10.1161/CIRCRESAHA.109.206615 · DOI
- 10.1007/s11745-001-0843-0 · DOI
- 10.1016/S0026-0495(98)90064-6 · DOI
- 10.1073/pnas.222421399 · DOI
- 10.1074/jbc.M502264200 · DOI · Paper page
- 10.1161/01.CIR.0000092889.24713.DC · DOI
- 10.1074/jbc.M302181200 · DOI
- 10.1074/jbc.M807683200 · DOI
- 10.1161/ATVBAHA.109.199158 · DOI
- 10.1126/science.204996 · DOI
- 10.1194/jlr.R024075 · DOI
- 10.1016/j.atherosclerosis.2015.06.028 · DOI
- 10.1161/ATVBAHA.113.301373 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.107.707349 · DOI
- 10.1161/01.ATV.0000259357.42089.dc · DOI
- 10.1097/MOL.0b013e328357ba61 · DOI
- 10.1016/j.bbalip.2013.01.003 · DOI
- 10.1161/CIRCRESAHA.110.219188 · DOI
- 10.1042/BJ20020306 · DOI
- 10.1074/jbc.M101726200 · DOI · Paper page
- 10.1074/jbc.272.20.13242 · DOI
- 10.1161/ATVBAHA.108.176487 · DOI
- 10.1194/jlr.M300231-JLR200 · DOI
- 10.1194/jlr.M020743 · DOI
Cited by
Sorted by citations
Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00195.2021 · Cited by 154
Metadata
- Authors
- Takiguchi, S., Ayaori, M., Yakushiji, E., Nishida, T., Nakaya, K., Sasaki, M., Iizuka, M., Uto-Kondo, H., Terao, Y., Yogo, M., Komatsu, T., Ogura, M., & Ikewaki, K.
- Affiliations
- From the Division of Anti-Aging and Vascular Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan (S.T., M.A., E.Y., T.N., K.N., M.S., M.I., H.U.-K., Y.T., M.Y., T.K., K.I.)
- Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center, Osaka, Japan (M.O.).
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2018-07
- Volume
- 38
- Issue
- 7
- Pages
- 1454-1467
- ISSN
- 1079-5642
- 1524-4636
- PMC
- PMC6039415
- Cited by
- 25
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review